Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:abbreviation |
gptkb:Wuxi_AppTec
|
| gptkbp:CEO |
gptkb:Ge_Li
|
| gptkbp:country |
gptkb:China
|
| gptkbp:foundedIn |
2000
|
| gptkbp:founder |
gptkb:Ge_Li
|
| gptkbp:headquartersLocation |
gptkb:Shanghai
|
| https://www.w3.org/2000/01/rdf-schema#label |
Wuxi AppTec
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:listedOn |
gptkb:Fortune_China_500
|
| gptkbp:netIncome |
~RMB 8.05 billion (2022)
|
| gptkbp:notableClient |
global pharmaceutical companies
|
| gptkbp:numberOfEmployees |
~36,000
|
| gptkbp:parentCompany |
Wuxi AppTec Group
|
| gptkbp:revenue |
~RMB 39.36 billion (2022)
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:services |
contract research
contract development manufacturing services |
| gptkbp:stockExchange |
gptkb:Hong_Kong_Stock_Exchange
gptkb:Shanghai_Stock_Exchange |
| gptkbp:stockSymbol |
2359
603259 |
| gptkbp:subsidiary |
gptkb:WuXi_Biologics
|
| gptkbp:website |
https://www.wuxiapptec.com/
|
| gptkbp:bfsParent |
gptkb:Shanghai_ChemPartner
|
| gptkbp:bfsLayer |
7
|